Abstract
Background and Purpose
Methods
Results
Supplementary materials
Notes
Disclosure
Gregory W. Albers reports equity and consulting for iSchemaView and consulting from Medtronic; Jens Fiehler reports grants and personal fees from Acandis, Cerenovus, MicroVention, Medtronic, Stryker, Phenox and grants from Route 92 outside the submitted work; Jeremy J. Heit reports consulting for Medtronic and MicroVention and Medical and Scientific Advisory Board membership for iSchemaView; Tobias D. Faizy reports grants from the German Research Foundation (DFG) during the conduct of the study.
ACKNOWLEDGMENTS
References
Table 1.
Variable |
ASPECTS ≤5 |
|||
---|---|---|---|---|
All patients (n=98) | mRS 4–6 (PCO) (n=76) | mRS 0–3 (GCO) (n=22) | P * | |
Patient characteristics | ||||
Age (yr) | 77 (64–82) | 77 (66–83) | 65 (57–78) | 0.010† |
Male sex | 42/98 (42.9) | 28/76 (36.8) | 14/22 (63.6) | 0.025‡ |
Atrial fibrillation | 35/98 (35.7) | 29/76 (38.2) | 6/22 (27.3) | 0.348‡ |
Hypertension | 72/98 (73.5) | 58/76 (76.3) | 14/22 (63.6) | 0.236‡ |
Diabetes | 21/98 (21.4) | 16/76 (21.1) | 5/22 (22.7) | 0.866‡ |
Glucose (mg/dL)§ | 129 (113–158) | 131 (114–163) | 126 (107–141) | 0.211† |
Lipid disorder | 24/89 (27.0) | 19/70 (27.1) | 5/19 (26.3) | 0.943‡ |
Smoking (current/former) | 21/98 (21.4) | 16/76 (21.1) | 5/22 (22.7) | 0.866‡ |
Admission NIHSS | 18 (14–20) | 19 (16–21) | 12 (9–18) | <0.001† |
Imaging characteristics | ||||
Location of arterial occlusion | 0.745‡ | |||
ICA | 31/98 (31.6) | 25/76 (32.9) | 6/22 (27.3) | |
MCA: M1 | 61/98 (62.2) | 47/76 (61.8) | 14/22(63.6) | |
MCA: M2 | 6/98(6.1) | 4/76 (5.3) | 2/22 (9.1) | |
ASPECTS, median (range) | 5 (0–5) | 4 (0–5) | 5 (3–5) | 0.002† |
0–2 | 12/98 (12.2) | 12/76 (15.7) | 0/22 (0.0) | |
3 | 17/98 (17.3) | 15/76 (19.7) | 2/22 (9.1) | |
4 | 20/98 (20.4) | 17/76 (22.4) | 3/22 (13.6) | |
5 | 49/98 (50.0) | 32/76 (42.1) | 17/22 (77.3) | |
Baseline ischemic core volume (CBF <30%) (mL)∥ | 35 (16–78) | 36 (16–87) | 34 (15–75) | <0.712† |
COVES | 1 (1–2) | 1 (0–2) | 2 (1–3) | <0.001† |
0 | 23/98 (23.5) | 21/76 (27.6) | 2/22(9.1) | |
1 | 35/98 (35.7) | 31/76 (40.8) | 4/22 (18.2) | |
2 | 22/98 (22.4) | 16/76 (21.1) | 6/22 (27.3) | |
3 | 12/98 (12.2) | 6/76 (7.9) | 6/22 (27.3) | |
4 | 6/98 (6.1) | 2/76 (2.6) | 4/22 (18.2) | |
5–6 | 0/98 (0) | 0/76 (0) | 0/22 (0) | |
Favorable VO profile (COVES ≥3) | 18/98 (18.4) | 8/76 (10.5) | 10/22 (45.5) | <0.001‡ |
Favorable arterial collaterals (Maas score ≥3) | 34/98 (34.7) | 22/76 (28.9) | 12/22 (54.5) | 0.026‡ |
Values are presented as median (interquartile range) or number (%) unless otherwise indicated.
ASPECTS, Alberta Stroke Program Early CT Score; mRS, modified Rankin Scale; PCO, poor clinical outcome; GCO, good clinical outcome; NIHSS, National Institutes of Health Stroke Scale; ICA, internal carotid artery; MCA, middle cerebral artery; CBF, cerebral blood flow; COVES, Cortical Vein Opacification Score; VO, venous outflow.
Table 2.
Variable |
ASPECTS ≤5 |
|||
---|---|---|---|---|
All patients (n=98) | mRS 4–6 (PCO) (n=76) | mRS 0–3 (GCO) (n=22) | P * | |
Procedural characteristics | ||||
Time from symptom onset to imaging (min)§ | 221 (131–419) | 210 (121–412) | 257 (193–440) | 0.343† |
Time from imaging to reperfusion (min)∥ | 79 (40–109) | 76 (41–109) | 87 (35–123) | 0.925† |
Administration of tPA | 52/98 (53.1) | 41/76 (53.9) | 11/22 (50.0) | 0.744‡ |
Mechanical thrombectomy | 88/98 (89.8) | 68/76 (89.5) | 20/22 (90.9) | 0.845‡ |
General anesthesia | 38/98 (38.8) | 32/76 (42.1) | 6/22 (27.3) | 0.209‡ |
Recanalization outcomes | 0.050‡ | |||
TICI 0 | 14/88 (15.9) | 14/68 (20.6) | 0/20 (0) | |
TICI 1 | 0/88 (0) | 0/68 (0) | 0/20 (0) | |
TICI 2a | 10/88 (11.4) | 7/68 (10.3) | 3/20 (15.0) | |
TICI 2b | 26/88 (29.5) | 22/68 (32.4) | 4/20 (20.0) | |
TICI 2c | 2/88 (2.3) | 2/68 (2.9) | 0/20 (0) | |
TICI 3 | 36/88 (40.9) | 23/68 (33.8) | 13/20 (65.0) | |
Good mechanical recanalization (TICI 2b/2c/3) | 64/88 (72.7) | 47/68 (69.1) | 17/20 (85.0) | 0.161‡ |
Excellent mechanical recanalization (TICI 2c/3) | 38/88 (43.2) | 25/68 (36.8) | 13/20 (65.0) | 0.025‡ |
Clinical outcomes | ||||
24-Hour NIHSS | 17 (9–22) | 19 (14–24) | 6 (3–9) | <0.001† |
mRS score at 90-day follow-up | 5 (4–6) | 5 (5–6) | 2 (1–3) | <0.001† |
mRS 0–2 | 12/98 (12.2) | 0/76 (0) | 12/22 (54.5) | |
mRS 0–3 | 22/98 (22.4) | 0/76 (0) | 22/22 (100.0) | |
mRS 4–5 | 42/98 (42.9) | 42/76 (55.3) | 0/22 (0) | |
mRS 6 | 34/98 (34.7) | 34/76 (44.7) | 0/22 (0) |
Values are presented as median (interquartile range) or number (%).
ASPECTS, Alberta Stroke Program Early CT Score; mRS, modified Rankin Scale; PCO, poor clinical outcome; GCO, good clinical outcome; tPA, tissue plasminogen activator; TICI, thrombolysis in cerebral infarction; NIHSS, National Institutes of Health Stroke Scale.
Table 3.
Ninety-eight patients included. Akaike Information Criterion=77.25. R2=0.56. Statistical significance: P<0.05.
mRS, modified Rankin Scale; ASPECTS, Alberta Stroke Program Early CT Score; aOR, adjusted odds ratio; CI, confidence interval; NIHSS, National Institutes Health Stroke Scale; COVES, Cortical Vein Opacification Score; tPA, tissue plasminogen activator; TICI, thrombolysis in cerebral infarction.